Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV. (Q50421953)

1 July 2018

title

Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV. (English)

1 reference

1 July 2018

main subject

chronic myeloid leukemia

0 references

6

Sebastien Rinaldetti

1 reference

1 July 2018

23

Andreas Hochhaus

1 reference

1 July 2018

3

Alice Fabarius

1 reference

Elisabeth Oppliger Leibundgut

1 July 2018

PMCID

5940636

16

object named as

Elisabeth Oppliger Leibundgut

1 reference

1 July 2018

8

Hermann Einsele

1 reference

1 July 2018

Michael Pfreundschuh

14

object named as

Michael Pfreundschuh

1 reference

1 July 2018

Markus Pfirrmann

21

object named as

Markus Pfirrmann

0 references

author name string

Susanne Saussele

1

1 reference

1 July 2018

Rüdiger Hehlmann

2

1 reference

1 July 2018

Sabine Jeromin

4

1 reference

1 July 2018

Ulrike Proetel

5

1 reference

1 July 2018

Katharina Kohlbrenner

7

1 reference

1 July 2018

Christiane Falge

9

1 reference

1 July 2018

Lothar Kanz

10

1 reference

1 July 2018

Andreas Neubauer

11

1 reference

1 July 2018

Michael Kneba

12

1 reference

1 July 2018

Frank Stegelmann

13

1 reference

1 July 2018

Cornelius F Waller

15

1 reference

1 July 2018

Dominik Heim

17

1 reference

1 July 2018

Stefan W Krause

18

1 reference

1 July 2018

Wolf-Karsten Hofmann

19

1 reference

1 July 2018

Joerg Hasford

20

1 reference

1 July 2018

Markus Pfirrmann

21

1 reference

1 July 2018

Martin C Müller

22

1 reference

1 July 2018

Michael Lauseker

24

1 reference

1 July 2018

publication date

26 February 2018

1 reference

1 July 2018

number of pages

7

1 reference

based on heuristic

inferred from page(s)

published in

Leukemia

1 reference

1 July 2018

volume

32

1 reference

1 July 2018

page(s)

1222-1228

1 reference

1 July 2018

issue

5

1 reference

1 July 2018

Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International

copyright license

start time

26 February 2018

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

exact match

https://scigraph.springernature.com/pub.10.1038/s41375-018-0055-7

0 references

cites work

Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5940636

The concept of treatment-free remission in chronic myeloid leukemia

3 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5940636

Tyrosine kinase inhibitors as a first-line treatment in patients with newly diagnosed chronic myeloid leukemia in chronic phase: A mixed-treatment comparison.

3 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5940636

Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study.

3 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5940636

Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia

3 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5940636

Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV.

3 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5940636

Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV.

3 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5940636

Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial

3 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5940636

Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006).

3 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5940636

Equivalence of BCR-ABL transcript levels with complete cytogenetic remission in patients with chronic myeloid leukemia in chronic phase.

3 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5940636

Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib

3 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5940636

Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION).

3 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5940636

Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors

3 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5940636

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.

3 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5940636

The EUTOS prognostic score: review and validation in 1288 patients with CML treated frontline with imatinib.

3 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5940636

Standardized definitions of molecular response in chronic myeloid leukemia.

3 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5940636

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

3 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5940636

Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)

3 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5940636

Harmonization of molecular monitoring of CML therapy in Europe

3 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5940636

Dynamic predicting by landmarking as an alternative for multi-state modeling: an application to acute lymphoid leukemia data

3 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5940636

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

3 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5940636

Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results

3 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5940636

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants.

3 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5940636

Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV.

14 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5940636

Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study.

14 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5940636

Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score

14 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5940636

Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia.

14 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5940636

10.1038/S41375-018-0055-7

14 August 2018

Identifiers

DOI

1 reference

1 July 2018

PMCID

5940636

1 reference

1 July 2018

PubMed ID

29479070

1 reference

1 July 2018